检索结果 - Keith W. Pratz

Refine Results
  1. 1
    Acute myeloid leukemia in the elderly: therapeutic options and choice

    Acute myeloid leukemia in the elderly: therapeutic options and choice 由 Jonathan Webster, Keith W. Pratz

    出版 2017
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  2. 2
    How I treat FLT3-mutated AML

    How I treat FLT3-mutated AML 由 Keith W. Pratz, Mark J. Levis

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Recent advances in targeted therapies in acute myeloid leukemia

    Recent advances in targeted therapies in acute myeloid leukemia 由 Rahul S. Bhansali, Keith W. Pratz, Catherine Lai

    出版 2023
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  4. 4
    Two novel germline DDX41 mutations in a family with inherited myelodysplasia/acute myeloid leukemia

    Two novel germline DDX41 mutations in a family with inherited myelodysplasia/acute myeloid leukemia 由 R. Li, N. Sobreira, P. Dane Witmer, Keith W. Pratz, Evan M. Braunstein

    出版 2016
    获取全文
    Carta
    加到收藏夹
    Saved in:
  5. 5
    FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

    FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML 由 Keith W. Pratz, Takashi Sato, Kathleen M. Murphy, Adam Stine, Trivikram Rajkhowa, Mark J. Levis

    出版 2009
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia

    Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia 由 Jessica K. Altman, James M. Foran, Keith W. Pratz, Denise Trone, Jorge E. Cortés, Martin S. Tallman

    出版 2017
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients

    Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients 由 Maria Cristina Villarroel, Keith W. Pratz, Linping Xu, John J. Wright, B. Douglas Smith, Michelle A. Rudek

    出版 2011
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

    Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study 由 Alexander E. Perl, Naval Daver, Keith W. Pratz, Joseph Maly, Wan‐Jen Hong, Erkut Bahceci, Bo Tong, Tian Tian, Kimberley Dilley

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase–Driven Leukemias and Other Malignancies

    Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase–Driven Leukemias and Other Malignancies 由 J. Kyle Bruner, S. Hayley, Li Li, Alice Can Ran Qin, Michelle A. Rudek, Richard J. Jones, Mark J. Levis, Keith W. Pratz, Christine A. Pratilas, Donald Small

    出版 2017
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

    A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response 由 Keith W. Pratz, Jorge E. Cortés, Gail J. Roboz, Niranjan Rao, Omotayo Arowojolu, Adam Stine, Yukimasa Shiotsu, Aiko Shudo, Shiro Akinaga, Donald Small, Judith E. Karp, Mark J. Levis

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Outcomes in Patients with Poor-Risk Cytogenetics with or without <i>TP53</i> Mutations Treated with Venetoclax and Azacitidine

    Outcomes in Patients with Poor-Risk Cytogenetics with or without <i>TP53</i> Mutations Treated with Venetoclax and Azacitidine 由 Daniel A. Pollyea, Keith W. Pratz, Andrew H. Wei, Vinod Pullarkat, Brian A. Jonas, Christian Récher, Sunil Babu, Andre C. Schuh, Monique Dail, Yan Sun, Jalaja Potluri, Brenda Chyla, Courtney D. DiNardo

    出版 2022
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation

    HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation 由 Amer M. Zeidan, Patrick M. Forde, Heather J. Symons, Allen Chen, Benjamin D. Smith, Keith W. Pratz, Hetty E. Carraway, Douglas E. Gladstone, Ephraim J. Fuchs, Leo Luznik, Richard J. Jones, Javier Bolaños‐Meade

    出版 2013
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML

    Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML 由 Amy Sexauer, Alexander E. Perl, Xiaochuan Yang, Michael J. Borowitz, Christopher D. Gocke, Trivikram Rajkhowa, Christian Thiede, Mark G. Frattini, Grant E. Nybakken, Keith W. Pratz, Judith E. Karp, B. Douglas Smith, Mark J. Levis

    出版 2012
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms

    A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms 由 Joshua F. Zeidner, J. E. Karp, Amanda L. Blackford, B. D. Smith, Ivana Gojo, Steven D. Gore, Mark J. Levis, Hetty E. Carraway, Judith M. Greer, S. Percy Ivy, Keith W. Pratz, Michael A. McDevitt

    出版 2013
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

    Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) 由 Keith W. Pratz, Mohamad Cherry, Jessica K. Altman, Brenda Cooper, José C. Cruz, Joseph G. Jurcic, Mark J. Levis, Tara L. Lin, Alexander E. Perl, Nikolai A. Podoltsev, Gary J. Schiller, Chaofeng Liu, Erkut Bahceci

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    Impact of <i>F</i> <i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

    Impact of <i>F</i> <i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia 由 Marina Konopleva, Michael J. Thirman, Keith W. Pratz, Jacqueline S. Garcia, Christian Récher, Vinod Pullarkat, Hagop M. Kantarjian, Courtney D. DiNardo, Monique Dail, Yinghui Duan, Brenda Chyla, Jalaja Potluri, Catherine L. Miller, Andrew H. Wei

    出版 2022
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

    A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias 由 Keith W. Pratz, E Cho, Mark J. Levis, Judith E. Karp, Steven D. Gore, Michael A. McDevitt, Adam Stine, Ming Zhao, Sharyn D. Baker, Michael A. Carducci, James R. Wright, Michelle A. Rudek, B. Douglas Smith

    出版 2010
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy

    Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy 由 Daniel A. Pollyea, Keith W. Pratz, Brian A. Jonas, Anthony Letai, Vinod Pullarkat, Andrew H. Wei, Marina Konopleva, Christian Récher, Olga Frankfurt, David A. Rizzieri, Tu Xu, Monique Dail, Brenda Chyla, Jalaja Potluri, Courtney D. DiNardo

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

    ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine 由 Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat, Michael J. Thirman, Christian Récher, Andre C. Schuh, Sunil Babu, Monique Dail, Grace Ku, Yan Sun, Jalaja Potluri, Brenda Chyla, Daniel A. Pollyea

    出版 2022
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study

    Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study 由 Daniel A. Pollyea, Keith W. Pratz, Anthony Letai, Brian A. Jonas, Andrew H. Wei, Vinod Pullarkat, Marina Konopleva, Michael J. Thirman, Martha Arellano, Pamela S. Becker, Brenda Chyla, Wan‐Jen Hong, Qi Jiang, Jalaja Potluri, Courtney D. DiNardo

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: